Sign in

Postmenopausal Osteoporosis Market is Estimated To Witness High Growth Owing To Rising Prevalence of Osteoporosis

Mia Yates
Postmenopausal Osteoporosis Market is Estimated To Witness High Growth Owing To Rising Prevalence of Osteoporosis

The Postmenopausal Osteoporosis Market is estimated to be valued at US$ 4747.9 Mn in 2023 and is expected to exhibit a CAGR of 4.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Postmenopausal osteoporosis refers to osteoporosis in women after menopause. It is characterized by low bone mass and structural deterioration of bone tissue, leading to bone fragility and an increased susceptibility to fractures, especially of the hip, spine, and wrist. Drugs prescribed for postmenopausal osteoporosis help reduce the risk of fractures by preventing further bone loss and helping rebuild bone density.

Market key trends:

One of the key drivers of the postmenopausal osteoporosis market is the rising prevalence of osteoporosis globally. As per data by the International Osteoporosis Foundation, globally around 9.9 million new osteoporotic fractures occur in people aged 60 years and over, including 1.6 million hip fractures globally each year. Furthermore, about 1 in 3 women and 1 in 5 men over the age of 50 worldwide will experience an osteoporotic fracture during their remaining lifetime. As the aging population increases rapidly, especially in developed nations, the incidence and prevalence of osteoporosis and related fractures are expected to rise significantly over the coming decades. This will consequently boost demand for postmenopausal osteoporosis treatments.

Porter’s Analysis

Threat of new entrants: The market requires huge capital investment and manufacturing facilities to produce pharmaceutical drugs. Additionally, stringent regulations are barriers for new entrants.

Bargaining power of buyers: The buyers have moderate bargaining power as there are substitute drugs available for postmenopausal osteoporosis treatment. However, patents offer market exclusivity to established players.

Bargaining power of suppliers: The suppliers have low bargaining power as raw materials used in drug manufacturing are commoditized and available off-shelf. Manufacturers can switch to alternate suppliers easily.

Threat of new substitutes: New biologic therapies and pipeline drugs pose threat of substitution to existing drugs. However, patent protection limits immediate threat.

Competitive rivalry: High as leading players compete on the basis of drug efficacy, safety profile, brand perception and pricing.

SWOT Analysis

Strength: Established pipeline of drugs, strong R&D capabilities and financial resources to undertake clinical trials. Varied product portfolio to address changing market needs.

Weakness: High costs associated with new drug development and clinical trials. Patent expiries make products vulnerable to generics competition.

Opportunity: Rising osteoporosis incidence globally due to aging population presenting huge market potential. Emerging economies yet to be tapped fully.

Threats: Entry of low-cost generics eroding revenues and market share of branded drugs shortly after patent expiration. Regulatory uncertainties and pricing controls impact profitability.

Key Takeaways

The Global Postmenopausal Osteoporosis Market Size is expected to witness high growth, exhibiting CAGR of 4.4% over the forecast period, due to increasing geriatric population globally making them prone to osteoporosis. Asia Pacific dominated the market and is expected to grow at a fastest CAGR of 5.1% owing to large patient pool, advanced healthcare infrastructure and rising awareness levels.

Regional analysis: Asia Pacific dominates the postmenopausal osteoporosis market accounting for over 30% share. China leads the regional market and India is expected to witness highest growth prospects during the forecast period. Developed markets of North America and Europe also offer lucrative opportunities, though growth rate will be higher in Asia Pacific.

Key players: Key players operating in the postmenopausal osteoporosis market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Mylan N.V. (Viatris Inc.), Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, Ligand Pharmaceuticals Incorporated among others.

For More Insights, Read: https://www.newswirestats.com/postmenopausal-osteoporosis-market-demand-growth-and-regional-outlook-by-2030/

Mia Yates
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more